The pituitary-gonadal function in postmenopausal women with epithelial ovarian tumors

APMIS, Supplement

Volumn 105, Issue 74, 1997, Pages 5-27

  Blaakær, Jan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOGEN; CONJUGATED ESTROGEN; ESTRADIOL; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADORELIN AGONIST; GONADOTROPIN; GOSERELIN; HYPOPHYSIS HORMONE; INHIBIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TETRANECTIN; THYROTROPIN;

CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NONHUMAN; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 84865936829     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Adami H-O, Hsieh C-c, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 1250-1254.
2. Al-Timimi A, Buckley CH, Fox H. An immunohistochemical study of the incidence and significance of human gonadotrophin and prolactin binding sites in normal and neoplastic human ovarian tissue. Br J Cancer 1986; 53: 321-329.
3. Andersen AN, Hagen C, Lange P, Boesgaard S, Djursing H, Eldrup E, Micic S. Dopaminergic regulation ofgonadotropin levels and pulsatility in normal women. Fertil Steril 1987; 47:391-397.
4. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. Acta Obstet Gynecol Scand 1982; 61:261-263.
5. Bamford PN, Steele S J. Uterine and ovarian carcinoma in a patient receiving gonadotropin therapy. Case report. Br J Obstet Gynaecol 1982; 89:962-964.
6. Bandera CA, Cramer D W, Friedman A J, Sheets EE. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol 1995; 58:116-119.
7. Beamer WG, Tennent BJ. Gonadotropin uptake in genetic and irradiation models of ovarian tumorigenesis. Biol Reprod 1986; 34:761-770.
8. Ben-Jonathan N. Dopamine: A prolactin-inhibiting hormone. Endocr Rev 1985; 6:564-589.
9. Beral V. The epidemiology of ovarian cancer. In: Sharp F, Soutier WP, eds. Ovarian cancer - the way ahead. Chameleon Press, London. Royal College of Obstetricians and Gynaecologists. 1987:21-31.
10. Bergqvist A, Kullander S, Thorell J. A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxyprogesterone acetate. Acta Obstet Gynecol Scand Suppl 1981; 101:75-81.
11. Bex FJ, Corbin A, France E. Resistance to the mouse antifertility effects of LHRH agonists. Life Sei 1982; 30: 1263-1269.
12. Biskind MS, Biskind GS. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944; 55:176-179.
13. Blaakaer J, Bennett P, Micic S, Toftager-Larsen K, Hording U, Bock JE, Lebech PE. The post-operative gonadotropin level in post-menopausal women with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1993a;52:lll-116.
14. Blaakaer J, Djursing H, Hording U, Bennett P, ToftagerLarsen K, Bock JE, Lebech PE. The pituitary-gonadal axis in women with benign or malignant ovarian tumors. ActaEndocrinol 1992; 127:127-130.
15. Blaakaer J, Hogdall CK, Hording U, Bennett P, ToftagerLarsen K, Daugaard S, Bock J. Hormonal factors and prognosis in epithelial ovarian cancer: a multivariate analysis. Eur J Obstet Gynecol Reprod Biol 1993b; 51: 21-27.
16. Blaakaer J, Hogdall CK, Micic S, Toftager-Larsen K, Hording U, Bennett P, Bock J. Ovarian carcinoma serum markers and ovarian steroid activity - is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. Eur J Obstet Gynecol Reprod Biol 1995; 59:53-56.
17. Blaakaer J, Micic S, Morris ID, Hording U, Bennett P, Toftager-Larsen K, Djursing H, Bock JE. Immunoreactive inhibin-production in post-menopausal women with malignant epithelial ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993c; 52:105-110.
18. Blaakoer J, Basksted M, Micic S, Albrectsen P, Rygaard J, Bock J. Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv Genotype. Biol Reprod 1995a; 53:775-779.
19. Blaakær J, Micic S, Høgdall CK. Immunoreactive inhibin concentration in blood tested under variable sampling conditions. J Steroid Biochem Molec Biol 1996; 58(3): 325-328.
20. Blaustein A. Surface (germinal) epithelium and related neoplasms. Pathol Annu 1981; 16:247-294.
21. Bokser L, Zalatnai A, Serially AV. Inhibition of pituitarygonadal axis in mice by long term administration of DTrp-6-LHRH microcapsules. J Reprod Fertil 1989; 85: 569-574.
22. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60:592-598.
23. Bramley TA, Menzies GS, Baird DT. Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: Characterization, properties, and luteal phase levels. J Clin Endocrinol Metab 1985; 61:834-841.
24. Bremond AG, Claustrat B, Rudigoz RC, Seffert P, Corniau J. Estradiol, androstendione, testosterone, and dehydroepiandrosterone sulfate in the ovarian and peripheral blood of postmenopausal patients with and without endometrial cancer. Gynecol Oncol 1982; 14:119-124.
25. Burger HG. Inhibin: clinical physiology and cancer diagnosis. Reprod Fertil Dev 1991; 3:227-231.
26. Burger HG. Evidence for a negative feedback role of inhibin in follicle stimulating hormone regulation in women. Hum Reprod 1993a; 8:129-132.
27. Burger HG. Clinical Review 46 Clinical utility of inhibin measurements. J Clin Endocrinol Metab 1993b; 76: 1391-1396.
28. Bäckström T, Mählck CG, Kjellgren O. Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors. Gynecol Oncol 1983; 16:129-138.
29. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: A case report. J In Vitro Pert Embryo Transf 1987; 4:126-128.
30. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JWW. Hormonal profiles after the menopause. Br Med J 1976; 2:784-787.
31. Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995; 71:1046-1050.
32. Cornelisse MM, Bennett PE, Christiansen M, Blaakaer J, Gluud C, Andersen JR, Homann C, Garred P. Sex hormone binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditions. Clin Chim Acta 1994; 225:115-121.
33. Cramer DW, Hutchinson GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982; 307: 1047-1051.
34. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. JNCI Journal of the National Cancer Institute 1983; 71:711 -716.
35. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. JNCI Journal of the National Cancer Institute 1983; 71:717-721.
36. Cruickshank D J, Fullerton WT, Klopper A. The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987; 94:692-695.
37. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139266.
38. De Jong FH. Inhibin. Physiol Rev 1988; 68:555-607.
39. Dennefors BL, Janson PO, Knutson F, Hamberger L. Steroid production and responsiveness to gonadotropin in isolated stromal tissue of human postmenopausal ovaries. Am J Obstet Gynecol 1980; 136:997-1002.
40. Edwards RL, Zoidis T, Taylor CW. Endocrine studies in post-menopausal women with ovarian tumours. J Obstet Gynaecol Br Commonvv 1971; 78:467-477.
41. Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, Harmer CL, Blake PR, Chilvers CED. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302:259-262.
42. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25:215-221.
43. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists in gynaecological cancers. Hum Reprod 1994; 9:1364-1379.
44. Fathalla MF. Incessant ovulation - A factor in ovarian neoplasia? Lancet 1971; 2:163.
45. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ 1989; 299: 309-311.
46. Fox H. Sex cord-stromal tumours of the ovary. J Pathol 1985; 145:127-148.
47. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, Trichopoulos D, Beral V. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991a; 49:57-60.
48. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991b; 49: 61-65.
49. Garde SV, Sheth AR, Zaveri B J, Shah J, Hinduja I. Endo-metrium - An extragonadal source of inhibin. Indian J ExpBiol 1991; 29:889-896.
50. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA, Berens ME. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989; 63:280-288.
51. Goldberg GL, Runowiecz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - Is there a link? Am J Obstet Gynecol 1992; 166: 853-854.
52. Gondos B. Surface eptihelium of the developing ovary. Possible correlation with ovarian neoplasia. Am J Pathol 1975; 81:303-320.
53. Graves PE, Sunvit EA, Davis JR, Stouffer RL. Adenylate cyclase in human ovarian cancers: Sensitivity to gonadotropins and nonhormonal activators. Am J Obstet Gynecol 1985; 153:877-882.
54. Greenblatt RB, Colle ML, Mahesh VB. Ovarian and adrenal steroid production in the postmenopausal woman. Obstet Gynecol 1976; 47:383-387.
55. Gurusinghe CJ, Healy DL, Jobling T, Marners P, Burger HG. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 1995; 57:27-32.
56. Hahlin M, Crona N, Knutson F, Janson PO. Human granulosa cell tumor: stimulation of steroidogenesis by gonadotropins in vitro. Gynecol Oncol 1991; 40:201-206.
57. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992; 136:1204-1211.
58. Hartge P, Hoover R, McGowan L, Lesher L, Noms HJ. Menopause and ovarian cancer. Am J Epidemiol 1988; 127:990-998.
59. Hogdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 1993; 72: 2415-2422.
60. HogdaU CK, Hogdall EVS, Hording U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol 1991; 43:103-107.
61. Hogdall CK, Mogensen O, Tabor A, Mogensen B, Jakobsen AKM, Nørgaard-Pedersen B, Larsen SO, Clemmensen I. The role of serum tetranectin, CA 125 and a combined index as tumor markers in women with pelvic tumours. Gynecol Oncol 1995; 56:22-28.
62. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day A J, Rome R, Cambell J J. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993a; 329: 1539-1542.
63. Healy DL, Mamers P, Burger HG. Clinical and pathophysiological aspects of inhibin. Hum Reprod 1993b; 8: 138-140.
64. Heinonen PK, Koivula T, Pystynen P. Elevated progesterone levels in serum and ovarian venous blood in patients with ovarian tumors. Acta Obstet Gynecol Scand 1985; 64:649-652.
65. Heinonen PK, Tuimala R, Pyykkö K, Pystynen P. Periph-eral venous concentrations of oestrogens in postmenopausal women with ovarian cancer. Br J Obstet Gynaecol 1982; 89:84-86.
66. Heintz AP, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: A review. Obstet Gynecol 1985; 66:127-135.
67. Helgason S, Carlström K, Damber M-G, von Schoultz B. Gonadotropins and prolactin during estrogen replacement therapy. Acta Obstet Gynecol Scand 1981; 60: 515-516.
68. Hsueh AJW, Schaeffer JM. Gonadotropin-releasing hormone as a paracrine and neurotransmitter in extra-pituitary sites. J Steroid Biochem 1985; 23:757-764.
69. Hughes CL, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol 1991; 40:42-45.
70. Hunter VJ, Lee Daly PA-C, Helms M, Soper JT, Berchuck A, Clarke- Pearson DL, ' Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990; 163:1164-1167.
71. Högberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993; 48: 3849.
72. IFFS. Fertility drugs and ovarian cancer. Fertil Steril 1993; 60:406-408.
73. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schultz C-D, Emons G. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (GNRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995; 55:817-822.
74. Ishimura K, Matsuda H, Tatsumi H, Fujita H, Terada N, Kitamura Y. Ultrastructural changes in the ovaries of Sl/Slt mutant mice, showing deve- lopmental defiency of follicles and tubular adenomas. Arch Histol Jpn 1986; 49:379-389.
75. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1-12.
76. Jeppsson S, Karlsson S, Kullander S. Gonadal steroids, gonadotropins and endometrial histology in postmenopausal women with malignant ovarian tumors. Acta Obstet Gynecol Scand 1986; 65:207-210.
77. Jeppsson S, Kullander S, Rannevik G. Peripheral and ovarian concentrations of gonadal steroids and CEA in women with ovarian tumors. Acat Obstet Gynecol Scand 1982; 61:209-212.
78. Judd HL, Judd GE, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39:1020-1024.
79. Jäger W, Diedrich K, Wildt L. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril 1987; 48:675-678.
80. Kammerman S, Demopoulos RI, Raphael C, Ross J. Gonodotropic hormone binding to human ovarian tumors. Human Pathol 1981; 12:886-890.
81. Kavanagh J J, Roberts W, Townsend P, Hewitt S. Leupro-lide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7:115-118.
82. Kluft C, Clemmensen I, Brommer E JP, Gevers Leuven JA, Boks AL, Vellenga E. Quantitation of plasma levels of tetranectin - effects of oral contraceptives, pregnancy, treatment with L-asparginase and liver cirrhosis. Thromb Res 1989; 62:792-796.
83. Knecht M, Ranta T, Feng P, Shinohara O, Kevin JC. Gonadotropin-relesing hormone as a modulator of ovarian function. J Steroid Biochem 1985; 23:771-778.
84. Kullander S, Rausing A, Schally AV. LHRH agonist treatment in ovarian cancer. In: Klijn JGM, Paridaens R, Foekens JA, eds. Hormonal manipulation of cancer. Peptides, growth factors, and new (anti) steroidal agents. Raven Press, New York. 1987:353-356.
85. La Vecchia C, Francheschi S, Gallus G, Decarli A, Liberati A, Tognoni G. Incessant ovulation and ovarian cancer: A critical approach. Int J Epidemiol 1983; 12:161-164.
86. Lamberts SWJ, Timmers JM, Oosterom R, Verleun T, Rommerts FG, de Jong FH. Testosterone secretion by cultured arrhenoblastoma cells: Suppression by a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 1982; 54:450-454.
87. Lanzone A, Muscatello R, Fulghesu AM, Caruso A, Guida C, Mancuso S. Serum CA-125 levels do not depend on ovarian steroidogenesis. Fertil Steril 1990; 54:415-418.
88. Lappöhn RE, Burger HG, Bouma J, Bangah M, Krans M, De Bruijn HWA. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989; 321:790-793.
89. Lind M J, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmons D, Carmichael J, Harris AL. A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992; 65:621-623.
90. Ling N, DePaolo LV, Bicsak TA, Shimasaki S. Novel ovarian regulatory peptides: Inhibin, activin, and follistatin. Clin Obstet Gynecol 1990; 33:690-702.
91. Mahesh VB. Gonadotropins in the menopause. In: Keep van PA, Greenblatt RB, Albeaux-Femet M, eds. Consensus on menopause research. A summary of international opion. Lancaster. MTP. 1976:11-18.
92. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, Asch B, Schally A. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrolix (SB-75). Fertil Steril 1995; 63:282-287.
93. Marchant J. The effect of hypophysectomy on the development of ovarian tumours in mice treated with dimethylbenzanthracene. Br J Cancer 1961; 15:821-827.
94. Maison PL, Morris ID, Sun JG, Ibrahim ZHZ, Lieberman B A. Serum inhibin as an index of ovarian function in women undergoing pituitary suppression and ovarian stimulation in an in vitro fertilization program. Horm Res 1991;35:173-177.
95. MatzukMM,FinegoldMJ,SuJ-GJ,HsuehAJW,Bradley A. Alfa-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992; 360:313-319.
96. McGowan L, Norris HJ, Hartge P, Hoover R, Lesher L. Risk factors in ovarian cancer. Eur J Gynaecol Oncol 1988;9:195-199.
97. McLachlan RI, Matsumoto AM, Burger HG, deKretser DM, BremnerWJ. Relative roles of follicle-stimulating hormone and luteinizing hormone in the control of inhibin secretion in normal men. J Clin Invest 1988; 82:880-884.
98. McLachlan RI, Robertson DM, Healy DL, Burger HG, De Kretser DM. Circulating immunoreactive inhibin levels during the normal human menstrual cycle. Clin EndocrinolMetab 1987; 65:954-961.
99. McNeilly AS, Tsonis CG, Baird DT. Inhibin. Hum Reprod 1988;3:45-49.
100. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14:245-255.
101. Michael S, Taguchi O, Nishizuka Y. Changes in hypophyseal hormones associated with accelerated aging and tumorigenesis of the ovaries in neonatally thymectomized mice. Endocrinology 1981; 108:2375-2380.
102. Mintz B, Russell ES. Gene-induced embryological modifications of primordial germ cells in the mouse. J Exp Zool 1957; 134:207-237.
103. Mosgaard B, Lidegaard O, Andersen AN. Use of fertility drugs in Denmark 1973-1993. An analysis based on sale statistics. Acta Obstet Gynecol Scand 1995; 74:614-618.
104. Murphy ED. Hyperplastic and early neoplastic changes in the ovaries of mice after genie deletion of germ cells. J Natl Cancer Inst 1972; 48:1283-1295.
105. Murphy ED, Beamer VG. Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the WxAVv genotype. Cancer Research 1973; 33:721-723.
106. Mählck CG, Bäckström T, Kjellgren O. Plasma level of estradiol in patients with ovarian malignant tumors. Gynecol Oncol 1988; 30:313-320.
107. Mählck CG, Bäckström T, Kjellgren O, Selstam G. Plasma 20alfa-OH-progesterone in women with malignant epithelial "non-endocrine" ovarian tumors. Acta Obstet Gynecol Scand 1985; 64:515-518.
108. Mählck CG, Grankvist K, Bäckström T, Kjellgren O. Testosterone, SHBG and albumin in patients with ovarian carcinoma. Acta Obstet Gynecol Scand 1986; 65: 533538.
109. Mählck CG, Grankvist K, Kjellgren O, Bäckström T. Relationship between CA 125 and progesterone production in women with ovarian carcinoma. Cancer 1990a; 65: 2058-2063.
110. Mählck C-G, Grankvist K, Kjellgren O, Bäckström T. Human chorionic gonadotropin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma. Gynec Oncol 1990b; 36:219-225.
111. Nash J D, Ozols RF, Smyth J F, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989; 73: 10091016.
112. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, Beral V, Boyle P, Trichopoulos D. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991; 49:50-56.
113. Nishida M, Jimi S, Haji M, Hayashi I, Kai T, Tasaka H. Juvenile granulosa cell tumor in association with a high serum inhibin level. Gynecol Oncol 1991; 40:90-94.
114. Ohashi M, Hasegawa Y, Haji M, Igarashi M, Nawata H. Production of imimmoreactive inhibin by a virilizing ovarian tumour (Sertoli- Leydig tumour). Clin Endocrinol 1990; 33:613-618.
115. Parmar H, Rustin G, Lightman SL, Phillips RH, Hanham IW, Serially AV. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. BrMed J 1988; 296:1229.
116. Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988; 159:873-876.
117. Peterson CM, Ziminski S J. A long-acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol 1990; 76:264-267.
118. Pour PM, Redding TW, Paz-Bouza JI, Schally AV. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report. Cancer Lett 1988; 41:105-110.
119. Quinn MA, Baker HWG, Rome R, Fortune D, Brown JB. Response of a mucinous ovarian tumor of borderline malignancy to human chorionic gonadotropin. Obstet Gynecol 1983; 61:121-126.
120. Rajaniemi R, Kauppila A, Rönnberg L, Seiander K, Pystynen P. LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 1981; 101:83-86.
121. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986; 4:515-523.
122. Robertson DM, Tsonis CG, McLachlan RI, Handelsman DJ, Leask R, Baird DT, McNeilly AS, Hayward S, Healy DL, Findlay JK, Burger HG, De Kretser DM. Comparison of inhibin immunological and in vitro biological activities in human serum. J Clin Endocrinol Metab 1988; 67:438-443.
123. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990; 76:258263.
124. Rubin CR, Hoskins W J, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL. Prognostic factors for recurrence following negative second-look laparatomy in ovarian cancer patients treated with platinium-based chemotherapy. Gynecol Oncol 1991;42:137-141.
125. Rüssel ES, Fekete E. Analysis of W-series pleiotropism in the mouse: Effect of WvWv substitution on defenitive germ cells and on ovarian tumorigenesis. J Natl Cancer Inst 1958; 21:365-381.
126. Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet 1980; 18:318-324.
127. Schiff I. The effects of conjugated estrogens on gonadotropins. Fertil Steril 1980; 33:333-334.
128. Schneyer AL, Sluss PM, Whitcomb RW, Martin KA, Sprengel R, Crowley \VF. Precursors of alfa-inhibin modulate follicle-stimulating hormone receptor binding and biological activity. Endocrinol 1991; 129:1987-1999.
129. Serov SF, Scully RE, Sobin LH, eds. World Health Organization. Geneva: Roto-Sadag S.A., 1976.
130. Sherman BM, West JH, Korenman SG. The menopausal transition: Analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976; 42:629-636.
131. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: Where are we today? Fertil Steril 1994; 62:433-448.
132. Simon WE, Albrecht M, Hansel M, Dietel M, Hölzel F. Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983; 70:839-845.
133. Slotman B J, Kühnel R, Rao BR, Dijkhuizen GH, De Graaff J, Stolk JG. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989; 33:76-81.
134. Slotman BJ, Nauta J JP, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor pro' gesterone receptor content is a prognostic indicator. Cancer 1990; 66:740-744.
135. Speroff L, Glass RH, Käse NG, eds. Clinical gynecologic endocrinology and infertility. Baltimore: Williams & Wilkins, 1989.
136. Stadel B V. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975; 123:772-774.
137. Stenman U-H, Alfthan H, Vartiainen J, Lahtovirta P. Markers supplementing CA 125 in ovarian cancer. Ann Med 1995; 27:115-120.
138. Stouffer RL, Grodin MS, Davis JR, Surwit EA. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 1984; 59:441-446.
139. Swenerton KD, HislopTG, Spinelli J, LeRiche JC, YangN, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65:264-270.
140. Tennent BJ, Beamer WG. Ovarian tumors not induced by irradiation and gonadotropins in hypogonadal (hpg) mice. Biol Reprod 1986; 34:751-760.
141. Thompson MA, Adelson MD, Kaufman LM. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 1991; 72:1036-1041.
142. Velasco E, Leon JD, Malacara JM, Dávalos G, Cervantes F, Castillo J. Gonadotropins and prolactin serum levels during the perimenopausal period: correlation with diverse factors. Fertil Steril 1990; 53:56-60.
143. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer;. J Natl Cancer Inst 1982; 68:95-98.
144. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992a; 136:11841203.
145. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992b; 136:1212-1220.
146. Whittemore AS, Harris R, Itnyre J, Halpern J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. I. Methods. Am J Epidemiol 1992c; 136:1175-1183.
147. Whittemore AS, Wu ML, Paffenbarger RSJ, Sarles DL, Kampert JBGS, Jung DL, Ballon S, Hendrickson M, Mohle-Boetani J. Epithelial ovarian cancer and the ability to conceive. Cancer Res 1989; 49:4047-4052.
148. WHO. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1989; 18:538-545.
149. Wide L. Median charge and charge heterogeneity of human pituitary FSH, LH, and TSH. II. Relationship to sex and age. Acta Endocrinol 1985a; 109:190-197.
150. Wide L. Median charge and charge heterogeneity of human pituitary FSH, LH, and TSH. I. Zone electrophoresis in agarose suspension. Acta Endocrinol 1985b; 109: 181189.
151. Wide L. The regulation of metabolic clearance rate of human FSH im mice by variation of the molecular structure of the hormone. Acta Endocrinol 1986; 112:336-344.
152. Wide L, Naessén T. 17 beta-oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause. Clin Endocrinol 1994; 40:783-789.
153. Wimalasena J, Dostal R, MeehanD. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 1992; 46:345-350.
154. Wimalasena J, Meehan D, Cavallo C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 1991; 41:56-63.
155. Winther JSD, Faiman C, Reyes FI. Sex steroid production by the human fetus: Its role in morphogenesis and control by gonadotropins. In: Blandau RJ, Bergma D, eds. Morphogenesis and malformation of the genital system. New York. Alan R. Liss. 1977:41-58.
156. Wu ML, Whittemore AS, Paffenbarger RSJ, Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M, Mohle-Boetani J. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988; 128:1216-1227.
157. Yamoto M, Minami S, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human ovarian follicles during the menstrual cycle. J Clin Endocrinol Metab 1992; 74:989-993.
158. Yano T, Pinski J, Radulovic S, Schally AS. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sei 1994; 91: 1701-1705.
159. Zweers A, Boever JD, Serreyn R, Vandekerckhove D. Correlation between peripheral CA-125 levels and ovarian activity. Fertil Steril 1990; 54:409-414.